Hadassah Medical CenterHadassah Medical Center
   Home    About    Treatment In Israel    Contact 
Home > Physicians, Researchers

Dr. Hila Elinav

 

Specialist in Internal Medicine

Fellow in Infectious

Diseases

Aids center, Department of

Clinical Microbiology and Infectious Diseases

Hadassah Hebrew-University Hospital

Kiryat Hadassah P.O.B. 12000

Jerusalem 91120

ISRAEL

Fax number: 02-6422273

 

 

Date of Birth: 10/2/1970

Marital Status : Married with 3 children

Military service: 1988-1990, Israeli Air force.

 

Education

 

1995: B. Sc in Medical Sciences, Hebrew University, Jerusalem, Israel

1998: MD, Hebrew University Medical School, Jerusalem, Israel

 

Postdoctoral training

 

1999-2001: Rotating Internship, Hadassah University hospitals

2001-2005: Internal Medicine residency, Internal medicine ward A, Ein Kerem, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

2005-2006: Hematology department, Hadassah- Hebrew University Medical  Center, Jerusalem, Israel

2006: Residency in infectious diseases- Hadassah- Hebrew University Medical Center, Jerusalem, Israel

 

Academic appointments

 

2003: Instructor, Hebrew University medical school

 

Grants

 

Joint research grant of the Hebrew university and Hadassah medical center, 2004.

 

Awards

 

1993: Dean Scholarship-Excellency award for academic achievements during first year in medical school.

1995: Excellency award for academic achievements during pre-clinical  medical school years.

1997: Excellency award for academic achievements during clinical medical school years in medical school

1998: Class representative for medical students exchange program at Mount Sinai University Hospital, New-York, NY, USA

 

List of publications

 

1.  Plasma oxidizability and plasma carbonyls, markers of oxidative stress, in transplant patients.  Elinav H, Kohen R, Granot E. Trnasplant Proc 2001 sep 33(6):2918-9.

 

2.  Markers of oxidative stress in cyclosporine-treated and tracrolimus-treated children  after liver transplantation. Granot E, Elinav H, Kohen R. Liver  Transpl. 2002 May:8(5):469-475.

 

3.  Retroperitoneal fibrosis-clinical response to steroid treatment. Elinav H, .Hersko A ,Libobithch G, Naparstek Y Harefuah 2003 Mar;142 (3):166-169.

 

4.  Cholangiocarcinoma in primary sclerosing cholangitis: "chronicle of a death foretold"? Margalit M, Elinav H, Goldin E, Ilan Y.Harefuah. 2003 Jun;142(6):421-5, 486.

 

5.  Deep infection by Trichophyton rubrum in an immunocompromised patient. Nir-Paz R, Elinav H, Pierard GE, Walker D, Maly A, Shapiro M, Barton RC, Polacheck I.J Clin Microbiol. 2003 Nov;41(11):5298-301.

 

6.  Idiopathic liver involvement in Turner syndrome.  Elinav H, Israeli E, Shibolet O, Hershko A, Sela C, Migdal A, Ilan Y. Isr Med Assoc J. 2004 Jan;6(1):56-7. Review.

 

7.  The coexistence of Sweet`s syndrome and Still`s disease-is it merely a coincidence?  Elinav H, Maly A, Ilan Y, Rubinow A, Naparstek Y,  Amital H.  J Am Acad Dermatol. 2004 May;50(5 Suppl):S90-2.

 

8.  Differential role of platelet granular mediators in angiogenesis. Brill A, Elinav H, (Co- authors )Varon D. Cardiovasc Res. 2004 Aug 1;63(2):226-35. Erratum in: Cardiovasc Res. 2004 Nov 1;64(2):374.

 

9.  Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. Margalit M, Elinav H, Ilan Y, Shalit M. J Gastroenterol Hepatol. 2004 Dec;19(12):1338-42.

 

10.  Plantar ulcers and eyebrow-hair paucity.  Elinav H, Palladas L, Appelbaum YH, Gilaed L,Moses AE, Cohen-Poradosu R. Clin Infect Dis. 2006 Mar 1;42(5):684-5, 722-4.

 

11. In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment.  Elinav H, Wolf Z, Szalat A, Bdolah-Abram T, Glazer B, Raz I, Leibowitz G., Curr Med Res Opin. 2007 Apr;23(4):757-65.

 

Abstracts and presentations in conferences

 

1.  Idiopathic liver involvement in Turner’s syndrome- a clinical study of 55 patients. Oral presentation at the Israel association for the study of the liver-February 2002.

 

2.  Chylous ascites-a clinical mystery-clinical presentation. Oral presentation at the Israel association for the   study of the liver-September 2002.

 

3.  The value of suPAR (Soluble urokinase-type plasminogen activator receptor) levels as a laboratory parameter of follow-up in HIV positive patients –poster presentation at the Israeli Infectious Disease conference-June 2007.

 




Dr. Hila Elinav


            
     
 


         Powered by